



Published in final edited form as:

AIDS. 2013 September 24; 27(15): 2431–2439. doi:10.1097/QAD.0b013e3283629117.

Toll-like Receptor (TLR) variants are associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level

Kristin M. BEIMA-SOFIE¹, Abigail W. BIGHAM⁸, Jairam R. LINGAPPA^{3,5,6}, Dalton WAMALWA¹⁰, Romel D. MACKELPRANG⁵, Michael J. Bamshad^{6,7}, Elizabeth MALECHE-OBIMBO¹⁰, Barbra A. RICHARDSON^{4,5,9}, and Grace C. JOHN-STEWART^{2,3,5,6}

¹Institute for Public Health Genetics, University of Washington, Seattle, USA

²Department of Epidemiology, University of Washington, Seattle, USA

³Department of Medicine, University of Washington, Seattle, USA

⁴Department of Biostatistics, University of Washington, Seattle, USA

⁵Department of Global Health, University of Washington, Seattle, USA

⁶Department of Pediatrics, University of Washington, Seattle, USA

⁷Department of Genome Sciences, University of Washington, Seattle, USA

⁸Department of Anthropology, University of Michigan, Ann Arbor, USA

⁹Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA

¹⁰Department of Paediatrics, University of Nairobi, Nairobi, Kenya

Abstract

Objective—We evaluated the association of single nucleotide polymorphisms (SNPs) in *TLRs* with infant HIV-1 acquisition and viral control.

Design—Infant HIV-1 outcomes were assessed in a Kenyan perinatal HIV-1 cohort.

Methods—Infants were genotyped for six candidate and 118 haplotype-tagging polymorphisms in *TLRs* 2, 3, 4, 7, 8, and 9, *MYD88* and *TIRAP*. Cox proportional hazards and linear regression were performed to assess associations with time to HIV-1 acquisition, time to infant mortality, and peak viral load (VL).

Results—Among 368 infants, 56 (15%) acquired HIV-1 by month 1 and 17 (4.6%) between 1 and 12 months. Infants with the *TLR9* 1635A (rs352140) variant were more likely to acquire HIV-1 by 1 month (HR=1.81, 95% confidence interval [CI]=1.05-3.14, p=0.033) and by 12 months (HR=1.62, CI=1.01-2.60, p=0.044) in dominant models adjusted for maternal plasma

Corresponding author: Kristin Beima-Sofie, Harborview Medical Center, Box 359909, 325 Ninth Avenue, Seattle, Washington 98104; Telephone: 206-897-6583; Fax: 206-543-4818; beimak@uw.edu.

Contributions: K.M.B., A.W.B., M.J.B., J.R.L. and G.C.J. conceived of the project. K.M.B. conducted the analysis with help from A.W.B., R.D.M. and B.A.R. K.M.B. and A.W.B. prepared samples. K.M.B. wrote the manuscript and all authors contributed to the final manuscript. D.W., E.O. and G.C.J. participated in the larger MTCT cohort study. G.C.J. and J.R.L. co-supervised the project and provided financial support for the study.

HIV-1 RNA level and genetic ancestry. Among 56 infants infected at 1 month of age, 1 copy of the *TLR9* 1635A allele was associated with a 0.58 log₁₀ c/ml lower peak VL (p=0.002). Female infants with 1 copy of the *TLR8* 1G (rs3764880) variant had a 0.78 log₁₀ c/ml higher peak VL (p=0.0009) and having 1 copy of the C allele for a haplotype tagging *TLR7* variant (rs1634319) was associated with a 0.80 log₁₀ c/ml higher peak VL in female infants (p=0.0003).

Conclusions—In this African perinatal cohort, we found several *TLR* polymorphisms associated with HIV-1 acquisition and progression. Defining mechanisms for these *TLR* associations may inform HIV-1 prevention strategies that leverage innate responses.

Keywords

pediatric HIV; mother-to-child transmission; genetic epidemiology; HIV genetics; innate immunity; single nucleotide polymorphisms; toll-like receptors; TLRs

Background

Recent studies demonstrate that innate immune responses play a critical role in HIV-1 acquisition and control [1-3]. This may be especially true in infants whose adaptive responses are still under development. Pattern Recognition Receptors (PRRs) are key effectors of the innate response that also bridge to adaptive immune response pathways. PRRs recognize evolutionarily conserved pathogen-associated molecular patterns (PAMPs) and PAMP recognition triggers activation of signal transduction pathways and downstream effector responses [4].

Toll-like receptors (TLRs) were the first mammalian PRRs discovered and 10 *TLR* genes have been identified in humans [5, 6]. Each TLR recognizes specific PAMPs characteristic of fungi, bacteria, viruses and/or parasites; TLRs 1, 2, and 4-6 preferentially recognize bacterial and fungal PAMPs while TLRs 3 and 7-9 preferentially recognize viral nucleic acids [2, 7]. Although TLR2 and TLR4 predominantly recognize bacterial motifs, they may also recognize viral components [5, 7]. TLR3 recognizes double-stranded RNA; TLRs 7 and 8 bind single-stranded RNA, and TLR9 recognizes unmethylated cytidine-phosphate-guanine (CpG) DNA motifs of bacteria and viruses [6].

All TLRs contain an extracellular leucine-rich repeat domain and an intracellular Toll/IL-1 Receptor homology (TIR) domain that binds to adaptor molecules involved in TLR-associated signaling cascades [4, 6, 8]. Biologic responses to TLR PAMP recognition are dependent on which TIR domain containing adaptor molecules are recruited and which signaling pathways are initiated. The TIR domain containing adapter-inducing interferon- β (TRIF)-dependent pathway induces the production of type I interferons and results in antiviral and immunoregulatory responses [4, 9] while the myeloid differentiation factor 88 (MyD88)-dependent pathway induces the production of proinflammatory cytokines and chemokines and induction of genes involved in antiviral response [8]. TIR domain containing adaptor protein (TIRAP), another TLR-adaptor molecule, functions mainly in TLR4 and TLR2 signaling either independently or in combination with MyD88 in the MyD88-dependent signaling pathway to upregulate NF- κ B and MAPKs [4, 8].

Because of their sentinel role in pathogen recognition and initiation of antiviral response, genetic variation in *TLR* and *TLR-associated* genes may influence HIV-1 acquisition and progression. Previous studies evaluating polymorphisms in *TLR2-TLR4* and *TLR7-TLR9* have shown that single nucleotide polymorphisms (SNPs) in *TLR* genes may contribute to differences in HIV-1 disease progression and acquisition [10-17]. Most notably, the *TLR9* 1635A/G variant has been associated with HIV-1 progression [12-14, 16]. However, the direction and strength of associations of this variant with HIV-1 progression differ between studies. The only study to date to evaluate associations between variants in *TLR9* and HIV-1 acquisition found a higher risk of HIV-1 acquisition in European children carrying a haplotype that included *TLR9* 1635A/G [17]. Studies in adults have also reported differences in HIV-1 disease progression or HIV-1 virus levels associated with SNPs in *TLR2* (597T/C), *TLR4* (896A/G and 1196C/T), *TLR7* (32A/T) and *TLR8* (1A/G) [10, 11, 13, 14]. Studies evaluating *TLR* variant associations with the presence of HIV-1 infection found that the *TLR7* 32A/T variant was detected more frequently in HIV-1 infected women compared to uninfected women [10] and the *TLR3* 1234C/T variant was significantly overrepresented in HIV-1-exposed seronegative (HESN) individuals when compared to healthy controls [15]. Other studies have shown correlations between levels of TLR mRNA, TLR protein expression, and TLR protein function with HIV-1 disease progression and acquisition in adult cohorts, further supporting the potential importance of *TLR* genetic variations for HIV-1 outcomes [11, 15, 18, 19].

The role of the innate immune system generally, and PRRs specifically, in pediatric HIV-1 infection remain largely unstudied. Furthermore, few HIV genetic studies have been conducted in African populations. We tested whether polymorphisms in *TLR* and *TLR-associated* genes are associated with altered risk of infant HIV-1 acquisition or disease progression in a perinatal African cohort.

Methods

Study Population and Sample

Our study used biological samples and phenotypic data collected from a cohort of mother-infant pairs recruited and followed between 1999 and 2005. As previously described, this cohort included 510 HIV-1-infected pregnant women who were enrolled at ~32 weeks gestation and mother-infant pairs were followed up to 2 years postpartum [20-23]. Briefly, HIV-1 seropositive pregnant women received standard antenatal care and short course zidovudine (ZDV) from 34-36 weeks gestation through delivery for the prevention of mother-to-child transmission (MTCT) [24]. Women were counseled on safe infant-feeding practices and elected to either breastfeed or formula feed their infants. Infants were evaluated monthly during the first year of life. Infant HIV-1 status was determined by DNA PCR assays at 48 hours of birth and at 2 weeks and 1, 3, 6, 9, and 12 months of age. We limited the analysis to DNA samples linked to infants of known sex and for whom time to HIV-1 acquisition could be determined. All participants provided written informed consent for the primary research study and for use of samples and data in future research. The Kenyatta National Hospital Ethical Review Committee (ERC) and the University of

Washington Institutional Review Board (IRB) specifically approved use of these biological samples and phenotypic data for this study.

Data Collection

Infant CD4 and CD8 percentages and lymphocyte counts were determined using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ) at the University of Nairobi, Kenya. Viral load was measured at the Fred Hutchinson Cancer Research Center in Seattle Washington, USA. Specifically, plasma HIV-1 RNA levels were quantified using the Gen-Probe transcription-mediated amplification assay. Previous studies have demonstrated that this assay is appropriate for quantifying the HIV-1 A, C, and D subtypes that are prevalent in Kenya [25]. Infant peripheral blood mononuclear cells (PBMCs) were isolated from EDTA anti-coagulated blood using a Ficoll gradient (Lymphocyte Separation Medium; Organon, Teknika), washed in RPMI 1640 medium (Sigma-Aldrich), and counted using trypan blue staining under a hemocytometer. Cells were cryopreserved at the University of Nairobi and sent to the United States for DNA extraction.

Cryopreserved cells were thawed and washed in R-10 media (RPMI with 10% FCS) and 1% PBS (Sigma-Aldrich). DNA was extracted using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA) and eluted in 20, 25, and 50 μ l of hydration buffer depending on estimated cell pellet size. DNA was quantified using a Spectra Max Gemina (Molecular Devices, Sunnyvale, CA) fluorimeter and the Quant-iT PicoGreen dsDNA Assay (Invitrogen, New York). Samples lacking 1 μ g of DNA (N=45) were whole genome amplified (WGA) using the REPLI-g Whole Genome Amplification Kit (Qiagen, Valencia, CA). Samples were genotyped using an Illumina Custom Oligo Pooled Assay (OPA) microarray platform (Illumina, Inc., San Diego, CA) designed for this study.

SNP Selection

We genotyped 124 SNPs in six *TLR* genes (TLRs 2, 3, 4, 7, 8 and 9) and two *TLR*-associated genes (*MYD88* and *TIRAP*). SNPs were selected using haplotype tagging and candidate SNP approaches. Haplotype tagging SNPs (TagSNPs) were selected using the LDSelect algorithm available through the University of Washington's genome variation server (<http://www.gvs.gs.washington.edu/GVS/>) using the r^2 threshold value of 0.8 and a minor allele frequency (MAF) cutoff value of 5% in the Yoruba (YRI) HapMap population [26, 27]. TagSNPs were augmented with six candidate SNPs, selected based on previously identified associations between variants in *TLRs* and HIV-1 outcomes [10-14] (Supplemental Table 1). To assess population stratification, we genotyped 144 ancestry informative markers (AIMS) distinguishing Asian, European and African (West and East) ancestry.

Quality Control

We excluded samples in which there was a discrepancy between the reported and experimentally determined sex (n=5) or which had >10% missingness (n=24). SNPs were excluded from the analysis if they were monomorphic (n=2), had >10% missingness (n=8), or violated Hardy-Weinberg equilibrium ($p < 0.001$) (n=1). TagSNPs with a MAF <5% in our sample population were also excluded (n=18). Overall, 29 of 397 infants and 29 of 118

SNPs did not meet quality control criteria and were excluded from this analysis (Supplemental Figure 1). In addition, five samples were genotyped in duplicate to estimate concordance rates in our genotyping platform. The genotype concordance rate was 100% for all successfully genotyped markers. Post-genotyping quality of WGA samples was evaluated and genotype frequencies for WGA and non-WGA samples were similar.

Data Analyses

Cox proportional hazards regression was performed to assess *TLR* polymorphism associations with time to HIV-1 acquisition by month 1 and month 12. Because viral load, CD4 count and ZDV use are collinear measures of maternal HIV-1 disease progression, genetic acquisition analyses were only adjusted for maternal viral load at 32 weeks gestation. Adjustment for population stratification was performed using the first principle component defined by EIGENSTRAT [28] analysis of genotyped AIMS.

Cox proportional hazards regression was performed to assess *TLR* polymorphism associations with time to infant mortality by 24 months in infants infected by month 1. Linear regression was performed to assess peak HIV-1 RNA levels in infected infants for infants infected by month 1 and month 12. All progression analyses were adjusted for genetic ancestry using the same method as the acquisition analysis.

All regression analyses were performed using Intercooled STATA 11.0 (College Station, USA). Sex-stratified analyses of the X chromosome genes, *TLR7* and *TLR8*, were conducted. For analysis with candidate *TLR* SNPs previously shown to be associated with HIV-1-specific outcomes, we did not adjust for multiple comparisons. All TagSNPs were adjusted for multiple comparisons using a Bonferroni correction to account for the 89 quality-controlled SNPs. All analyses were first performed assuming an additive model of inheritance. All candidate SNP analyses and TagSNPs showing uncorrected significant ($p < .05$) associations in additive models were rerun using dominant and recessive models of inheritance and the model best representing the association was selected.

Results

Cohort characteristics

Among 510 mother-infant pairs initially enrolled in a perinatal HIV-1 transmission cohort, 368 had samples available, passed quality control procedures, and were included in this analysis. Characteristics of these mother-infant pairs are provided in Table 1. Among the infants, 56 (15%) acquired HIV-1 by 1 month of age and 17 (4.6%) acquired HIV-1 between 1 and 12 months of age. Maternal CD4 counts at 32 weeks gestation were significantly lower in those who transmitted HIV-1 compared to those who did not (406 vs. 483 cells/ μ l, $p = 0.011$). Plasma HIV-1 RNA levels were significantly higher among women who transmitted HIV-1 compared to those who did not, both at 32 weeks gestation (5.11 vs. 4.56 \log_{10} copies/ml, $p < 0.001$) and at delivery (4.66 vs. 3.93 \log_{10} copies/ml, $p < 0.001$). Most women (89%) reported use of zidovudine for the prevention of mother-to-child transmission. Women who transmitted HIV-1 before one month were significantly less likely to report zidovudine use than those who did not transmit (OR=0.338, 95% confidence

interval [CI]: 0.159, 0.717; p -value=0.005). A similar association was noted for 12-month transmission (OR=0.43, 95% CI: 0.2, 0.89; p =0.023).

HIV-1 infected children experienced high rates of mortality with 45% of infants infected by 1 month of age dying before 12 months and 18% of infants infected between months 1 and 12 dying before reaching 12 months. Among the 56 infants HIV-1 infected at 1 month, the mean peak plasma HIV-1 RNA level was 6.8 \log_{10} copies/ml (\log_{10} c/mL) (Table 1).

HIV-1 Acquisition

The primary analysis endpoint was HIV-1 acquisition in infants. Infants with one or more copies of the candidate variant *TLR9* 1635A (rs352140) were more likely to acquire HIV-1 by 1 month (HR=1.81, 95% CI: 1.05, 3.14; p =0.033) and 12 months (HR=1.62, 95% CI: 1.01, 2.60; p =0.044) in dominant models adjusted for maternal plasma HIV-1 RNA levels and genetic ancestry (Figure 1). The *TLR9* 1635A allele association with time to HIV-1 acquisition remained significant at both time-points when evaluated using an additive model of inheritance and showed a trend for association at both acquisition time-points when assessed using a recessive model of inheritance. No other candidate or *TLR*, *TIRAP* or *MyD88* haplotype tagging SNPs were significantly associated with HIV-1 acquisition in analyses adjusted for multiple comparisons (Supplemental Table 2).

Peak Viral Load

We found associations between *TLR9* 1635G/A (rs352140), *TLR8* 1A/G (rs3764880), and *TLR7* rs1634319 variants and peak plasma HIV-1 RNA levels in HIV-1 infected infants (Figure 2 and Table 2). The presence of one or more copies of the *TLR9* 1635A allele was associated with 0.58 \log_{10} c/ml lower peak plasma HIV-1 RNA levels (95% CI: -0.95, -0.22; p =0.002) in infants infected by month 1 and with 0.49 \log_{10} c/ml lower peak plasma HIV-1 RNA levels (95% CI: -0.85, -0.12; p =0.009) in infants infected by month 12 using dominant models of inheritance. The association remained significant for both time points in additive models of inheritance and showed a trend for association with a recessive model of inheritance in infants infected by 1 month of age.

Female infants infected by 1 month of age and having one or more copies of the *TLR8* 1G allele (rs3764880) had a 0.78 \log_{10} c/ml higher peak viral load (95% CI: 0.35, 1.21; p <0.001); a similar association was seen in female infants infected by 12 months (0.65 \log_{10} c/ml higher peak viral load; 95% CI: 0.21, 1.10; p =0.005). The association remained significant at both infection time-points in additive models but not recessive models of inheritance. There was no significant association between peak plasma HIV-1 RNA levels and the *TLR8* 1A/G variant in male infants (Supplemental Table 3).

We also found an association between a haplotype tagging intronic variant in *TLR7* (rs1634319) and peak plasma HIV-1 RNA levels. Female infants infected by 1 year of age with 1 copy of the *TLR7* rs1634319 C allele had a 0.80 \log_{10} c/ml higher peak viral load (95% CI: 0.40, 1.20; corrected p =0.027 assuming a dominant model of inheritance and controlling for genetic ancestry. A similar association was noted among female infants infected by 1 month (mean difference=0.75; 95% CI: 0.30, 1.19; corrected p =0.17), but this

association was not significant after controlling for multiple comparisons. This variant showed no significant associations with peak plasma HIV-1 RNA levels in male infants. No other candidate or *TLR*, *TIRAP* or *MyD88* haplotype tagging SNPs were significantly associated with peak plasma HIV-1 RNA levels in analyses adjusted for multiple comparisons (Supplemental Table 3).

Mortality

Because of potential survival bias, we evaluated time to death only in infants infected by 1 month of age. We found no significant associations with time to death by any *TLR*, *TIRAP* or *MyD88* haplotype tagging SNP included in this analysis after adjusting for multiple comparisons and found no significant associations with candidate SNPs; however we had limited statistical power to evaluate associations with mortality. We noted a trend for association with mortality for two candidate SNPs (*TLR2* 1350T/C and *TLR7* 32A/T) (Supplemental Table 4). In infants infected by 1 month of age, the *TLR2* 1350CC (rs3804100) genotype had a trend for association with increased risk of mortality (HR=6.36; 95% CI: 0.97, 51.24; p=0.082) using a recessive model of inheritance and controlling for genetic ancestry. However the minor allele frequency for this polymorphism was low (4.92%) and only 1 infected infant had this genotype. We also saw a trend for association between each additional copy of the *TLR7* 32T (rs179008) allele and time to mortality in female infants infected by month 1 (HR=2.84, 95% CI: 0.87, 9.23; p=0.082).

Discussion

Few studies have evaluated the role of *TLR* genetic variation in infant HIV-1 acquisition and progression [16, 17] and our study is the first to evaluate the influence of *TLR* polymorphisms in a perinatal African cohort. We found that *TLR9* 1635G/A was associated with both HIV-1 acquisition and peak HIV-1 viral load, and *TLR8* 1A/G and the haplotype tagging *TLR7* variant (rs1634319) were associated with peak plasma HIV-1 RNA level.

We found that *TLR9* 1635G/A was associated with a higher risk of HIV-1 acquisition early (<1 month of age), and by the end of the first year of life. This supports a trend observed in a previous study evaluating *TLR9* genetic variations in HIV-1 MTCT [17]. However, in contrast, this variant was also reported to be associated with protection from HIV-1 acquisition in an African heterosexual serodiscordant couples cohort suggesting that this variant may exert different effects in heterosexual and vertical transmission [29]. While this seeming discrepancy in findings could reflect population differences in LD, it is notable that the two cohorts that had the greatest likelihood for differences in population stratification with one African and the other European, shared a common biological mode of HIV-1 transmission and had similar *TLR9* association results. Conversely, the African heterosexual couples and our vertical transmission cohorts share a common population background (Eastern African) but were distinct in the biological mode of HIV-1 transmission. These findings could suggest that the source of the discrepancy is in the functional role that *TLR9* plays in heterosexual HIV-1 acquisition compared to mother-to-child HIV-1 acquisition.

We also found that the *TLR9* 1635A allele was associated with a decrease in peak VL. The protective effect we found associated with the 1635A allele is consistent with one previous

study in adults of European ancestry [13] but contradicts the findings of two other HIV-1 progression studies in adults of European ancestry [12, 14] and one study in HIV-1 infected children of European ancestry [16]. Differences between these cohorts, including HAART use, population ancestry, and progression measures observed could have led to differences in *TLR* associations. Specifically, the timing during HIV disease course when these variants are being evaluated may have an impact in the observed phenotype for specific *TLR* variants. A differential effect of *TLR* variants on HIV-1 set point was noted in acute versus chronically infected African adults [29], and in a functional evaluation of TLR signaling in acute versus chronic infection [30]. In early HIV-1 infected infants, there is delayed containment or non-containment of HIV-1, making it difficult to evaluate set-point comparably to adults [31] and may contribute to the different effect we observed of *TLR9* 1635A on HIV-1 progression.

Our observation that *TLR9* 1635G/A was associated both with higher HIV-1 acquisition risk and lower peak viral load in HIV-1 infected infants may be explained by potentially distinct effects of *TLR9* on HIV-1 acquisition versus progression. In the context of HIV-1 uninfected infants, this response could increase recruitment of activated CD4+ T cells that serve as targets for HIV-1 replication. We could speculate that the *TLR9* variant was associated with recruitment of activated immune cells to infant mucosal environments where they serve as HIV-1 susceptible targets. However, *TLR9* is primarily expressed on plasmacytoid dendritic cells and mediates interferon- α release and antigen presentation thereby linking the innate and adaptive immune responses [12]. Thus, *TLR9*-mediated pro-inflammatory cytokine release could also initiate anti-HIV mechanisms that limit viral replication in already infected infants and decrease peak HIV-1 RNA levels.

The specific function of the *TLR9* 1635G/A variant in HIV-1 disease remains unknown. The G to A variation is a synonymous change in exon 2, making it difficult to infer any specific functional outcome. However, an intronic *TLR9* 1174A/G variant associated with decreased *TLR9* transcriptional activity [32] is found in high linkage disequilibrium (LD) ($r^2=0.98$) with 1635G/A in European but not African cohorts. This could explain the observed differences in association of the *TLR9* 1635G/A variant and HIV-1 disease progression in these distinct ancestral populations. Thus, it is possible that, in our sampled African cohort, the *TLR9* 1635G/A variant is in high LD with a different currently unidentified causal SNP. Alternatively, *TLR9* 1625G/A could alter mRNA splicing or stability, or protein expression or function, which has been documented for other synonymous changes [33].

We found that *TLR8* 1A/G was associated with peak HIV-1 RNA level. We found that one or more copies of the *TLR8* 1G allele was associated with a 0.78 \log_{10} c/ml higher peak HIV-1 RNA level in female but not male infants. In contrast, *Oh et al.* found that the *TLR8* 1G variant was protective against rapid CD4+ T-cell depletion in males of European ancestry [11]. This difference in associations could be due to differences between adult and pediatric HIV-1 progression, gender differences, or differences in outcome measure assessed [34, 35]. Infants have much more rapid HIV-1 disease progression than adults which may be due to the relatively weaker adaptive immune response in infants [35]. We also identified a novel *TLR7* variant (rs1634319) associated with higher peak plasma HIV-1 RNA levels in female infected infants. *TLR7* viral RNA recognition can lead either towards immune

activation and viral replication or an effective antiviral response [8]. The rs1634319 variant we identified is intronic but could influence TLR7 expression or be in linkage disequilibrium with another causal variant.

While previous studies evaluating genetic variations in *TLR2* and *TLR4* have found positive associations with HIV-1 progression outcomes, our study did not confirm these associations or identify new associations with *TLR2* or *TLR4*, nor did our study confirm a previously observed association between a *TLR7* variant (32A/T) and HIV-1 progression in adult males [10]. Our study found no associations between genetic variations in *TIRAP* or *MYD88* and HIV-1 acquisition or progression. We may not have detected specific associations because of relatively limited statistical power, unique properties of vertical HIV-1 transmission that differ from sexual HIV-1 transmission, or differences in allele frequencies in our population compared to other previously published cohorts.

In summary, this study is the first to evaluate the association between *TLR* polymorphisms and HIV-related outcomes in a perinatal African cohort and confirms that variations in *TLRs* may contribute to pediatric HIV-1 outcomes. Further studies are needed to define mechanisms underlying these associations and the specific functions of TLRs during the course of HIV-1 disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank the women and children who participated in the study, the University of Washington Northwest Genomics Center, the Center for Clinical Genomics at the University of Washington and K. Buckingham for technical assistance.

Sponsorship: This research was supported by National Institutes of Health (NIH) research grant R21 AI073115 and R01 HD023412. KBS was supported by the University of Washington Institute of Translational Health Sciences Multidisciplinary Clinical Research Training Program (TL1 TR 000422) from the National Center for Advancing Translational Sciences, National Institutes of Health and the Fogarty International Clinical Research Scholars Program (Grant Number 5 R24 TW007988) from National Institutes of Health, Fogarty International Center through Vanderbilt University. AWB was supported by a training fellowship from the NIH/National Human Genome Research Institute (T32 HG00035).


References

1. Ploquin MJ, Jacquelin B, Jochems SP, Barre-Sinoussi F, Muller-Trutwin MC. Innate immunity in the control of HIV/AIDS: recent advances and open questions. *AIDS*. 2012; 26(10):1269–79. [PubMed: 22472855]
2. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. *Retrovirology*. 2010; 7:54. [PubMed: 20569472]
3. Chang JJ, Altfield M. Innate immune activation in primary HIV-1 infection. *J Infect Dis*. 2010; 202(Suppl 2):S297–301. [PubMed: 20846036]
4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006; 124(4): 783–801. [PubMed: 16497588]
5. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. *Int Immunol*. 2009; 21(4):317–37. [PubMed: 19246554]

6. Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol.* 2003; 21:335–76. [PubMed: 12524386]
7. Murphy, K.; Travers, P.; Walport, M. *Immuno Biology.* 7. New York, New York: Garland Science; 2008.
8. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol.* 2010; 11(5):373–84. [PubMed: 20404851]
9. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. *Mol Immunol.* 2005; 42(8):859–67. [PubMed: 15829275]
10. Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kucherer C, et al. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. *AIDS.* 2009; 23(3):297–307. [PubMed: 19114863]
11. Oh DY, Taube S, Hamouda O, Kucherer C, Pogensee G, Jessen H, et al. A functional toll-like receptor 8 variant is associated with HIV disease restriction. *J Infect Dis.* 2008; 198(5):701–9. [PubMed: 18605904]
12. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez Mdel M, Salinas A, Pulido I, et al. Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. *J Acquir Immune Defic Syndr.* 2008; 49(2):128–35. [PubMed: 18769358]
13. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. *AIDS.* 2007; 21(4):441–6. [PubMed: 17301562]
14. Pine SO, McElrath MJ, Bochud PY. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. *AIDS.* 2009; 23(18): 2387–95. [PubMed: 19855253]
15. Sironi M, Biasin M, Cagliani R, Forni D, De Luca M, Saulle I, et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. *J Immunol.* 2012; 188(2):818–23. [PubMed: 22174453]
16. Freguja R, Gianesin K, Del Bianco P, Malacrida S, Rampon O, Zanchetta M, et al. Polymorphisms of innate immunity genes influence disease progression in HIV-1-infected children. *AIDS.* 2012; 26(6):765–8. [PubMed: 22269973]
17. Ricci E, Malacrida S, Zanchetta M, Mosconi I, Montagna M, Giaquinto C, et al. Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1. *J Transl Med.* 2010; 8:49. [PubMed: 20500814]
18. Sanders CM, Cruse JM, Lewis RE. Toll-like receptors, cytokines and HIV-1. *Exp Mol Pathol.* 2008; 84(1):31–6. [PubMed: 17997401]
19. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachhi C, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. *AIDS.* 2008; 22(6):685–94. [PubMed: 18356597]
20. Farquhar C, Rowland-Jones S, Mbori-Ngacha D, Redman M, Lohman B, Slyker J, et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. *AIDS Res Hum Retroviruses.* 2004; 20(7):692–7. [PubMed: 15307911]
21. Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. *J Infect Dis.* 2002; 186(8):1173–6. [PubMed: 12355371]
22. Otieno PA, Brown ER, Mbori-Ngacha DA, Nduati RW, Farquhar C, Obimbo EM, et al. HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. *J Infect Dis.* 2007; 195(2):220–9. [PubMed: 17191167]
23. Lohman BL, Slyker J, Mbori-Ngacha D, Bosire R, Farquhar C, Obimbo E, et al. Prevalence and magnitude of human immunodeficiency virus (HIV) type 1-specific lymphocyte responses in breast milk from HIV-1-seropositive women. *J Infect Dis.* 2003; 188(11):1666–74. [PubMed: 14639537]

24. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. *Lancet*. 1999; 353(9155):773–80. [PubMed: 10459957]
25. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. *J Clin Microbiol*. 2000; 38(7):2688–95. [PubMed: 10878065]
26. International HapMap Consortium. A haplotype map of the human genome. *Nature*. 2005; 437(7063):1299–320. [PubMed: 16255080]
27. International HapMap Consortium. The International HapMap Project. *Nature*. 2003; 426(6968): 789–96. [PubMed: 14685227]
28. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006; 38(8): 904–9. [PubMed: 16862161]
29. Mackelprang, RD.; Bigham, AW.; Celum, C.; Bruyn, Gd; Beima-Sofie, K.; John-Stewart, G., et al. Polymorphisms in TLR2 and TLR7 are associated with plasma HIV-1 RNA set point in an African heterosexual cohort. 19th International AIDS Conference; Washington, DC. 2012.
30. Chang JJ, Lacas A, Lindsay RJ, Doyle EH, Axten KL, Pereyra F, et al. Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection. *AIDS*. 2012; 26(5):533–41. [PubMed: 22210629]
31. Obimbo EM, Wamalwa D, Richardson B, Mbori-Ngacha D, Overbaugh J, Emery S, et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. *J Acquir Immune Defic Syndr*. 2009; 51(2):209–15. [PubMed: 19504753]
32. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. *Ann Rheum Dis*. 2007; 66(7):905–9. [PubMed: 17344245]
33. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. *Nat Rev Genet*. 2011; 12(10):683–91. [PubMed: 21878961]
34. Matt C, Roger M. Genetic determinants of pediatric HIV-1 infection: vertical transmission and disease progression among children. *Mol Med*. 2001; 7(9):583–9. [PubMed: 11778647]
35. Tiemessen CT, Kuhn L. Immune pathogenesis of pediatric HIV-1 infection. *Curr HIV/AIDS Rep*. 2006; 3(1):13–9. [PubMed: 16522254]

a: HIV Acquisition in infants infected by 1 month of age



b: HIV Acquisition in Infants infected by 12 months of age






Figure 1.
Time to HIV-1 Acquisition by TLR9 Genotype

Infants Infected by Month 1



Infants Infected by Month 12

**Figure 2.**

SNP Variations Associated with Peak Plasma HIV-1 RNA Levels (log₁₀ copies/ml) in Infants Infected with HIV-1 by 1 and 12 Months of Age*

NOTE: Log₁₀ peak plasma HIV-1 RNA levels are displayed separately for infants who acquired HIV-1 by 1 month of age and all infants who acquired HIV-1 by 12 months of age. Each graph presents the mean and standard deviation of peak plasma HIV-1 RNA level stratified by genotype and the p-value corresponding to the mean difference. The number of individuals in each genotypic category is specified on the x-axis next to the genotype.

* Uncorrected p-values are displayed for the TagSNP *TLR7* rs1634319

Cohort Characteristics

Table 1

Characteristic	Total Cohort		Positive by MI		Positive by MI2	
	N	Median (IQR) or Number (%)	N	Median (IQR) or Number (%)	N	Median (IQR) or Number (%)
Maternal (Prenatal)						
Maternal CD4+ T Cell Count (32 weeks gestation)*	364	433 (306-619)	56	420 (237-597)	72	371 (237-558)
Maternal HIV-1 Plasma RNA Level (32 weeks gestation)**	355	4.72 (4.19-5.24)	54	5.20 (4.72-5.44)	71	5.19 (4.72-5.54)
Maternal (Delivery and Postpartum)						
Maternal CD4+ T Cell Count (1 month postpartum)*	323	540 (370-731)	49	469 (319-629)	62	466 (311-604)
Maternal HIV-1 Plasma RNA Level (time of delivery)**	293	4.12 (3.51-4.69)	45	4.52 (4.02-5.09)	61	4.65 (4.06-5.26)
ZDV During Pregnancy	361	322 (89)	54	42 (78)	70	57 (81)
Infant						
HIV Positive	368	73 (20)*	56	56 (100)	73	73 (100)
Female	368	178 (48)	56	29 (52)	73	33 (45)
Completed 12 Months of Follow-up	368	296 (80)	56	28 (50)	73	42 (58)
Completed 24 Months of Follow-up	368	41 (11)	56	20 (35)	73	28 (38)
Infant deaths (12 months)	368	48 (13)	56	25 (45)	73	28 (38)
Infant deaths (24 months)	368	62 (17)	56	33 (59)	73	39 (53)
Whole Genome Amplification	368	45 (12)	56	9 (16)	73	11 (15)
Peak HIV-1 plasma RNA level**	-	-	56	6.77 (6.43-7.41)	73	6.71 (6.41-7.40)

* CD4+ T cell counts measured in cells/ μ l

** HIV-1 plasma RNA levels measured in log₁₀ copies/ml

*** Infants positive by 12 months of age

Table 2

SNP Variations Associated with Peak Plasma HIV-1 RNA Levels in HIV-1 Infected Infants

SNP	Model	Genotype	N (%)	Median Peak Viral Load (IQR)	Mean (SD)	Mean Difference (95% CI)	p-value
Transmission by Month 1							
rs352140	Dominant	GG	22 (39)	7.12 (6.71-7.60)	7.18 (0.58)	-0.581 (-0.946, -0.217)	0.0023
		GA or AA	34 (61)	6.54 (6.28-7.00)	6.60 (0.68)		
rs3764880	Dominant -Female Only	AA	13 (45)	6.52 (6.28-6.60)	6.38 (0.47)	0.783 (0.351, 1.214)	0.0009
		AG or GG	16 (55)	7.27 (6.65-7.57)	7.16 (0.61)		
rs1634319	Dominant -Female Only	TT	14 (48)	6.50 (6.30-6.75)	6.43 (0.47)	0.746 (0.302, 1.189)	0.0019*
		TC or CC	15 (52)	7.40 (6.56-7.58)	7.17 (0.64)		
Transmission by Month 12							
rs352140	Dominant	GG	31	7.09 (6.57-7.60)	7.04 (0.72)	-0.485 (-0.847, -0.123)	0.0094
		GA or AA	42	6.54 (6.28-7.00)	6.56 (0.78)		
rs3764880	Dominant -Female Only	AA	14	6.49 (6.22-6.60)	6.36 (0.46)	0.652 (0.208, 1.095)	0.0054
		AG or GG	19	7.02 (6.46-7.56)	7.01 (0.69)		
rs1634319	Dominant -Female Only	TT	17	6.46 (6.06-6.71)	6.34 (0.47)	0.7999 (0.400, 1.200)	0.0003**
		TC or CC	16	7.27 (6.58-7.57)	7.14 (0.63)		

* Bonferroni corrected p-value = 0.17

** Bonferroni corrected p-value = 0.027